TREAT study: Improving the interpretation of TRoponin concentrations following Exercise And Their clinical significance

TREAT study: Improving the interpretation of TRoponin concentrations following Exercise And Their clinical significance - TREAT study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51559

Enrollment

1500

Registered

2022-01-13

Start date

2022-06-15

Completion date

Unknown

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovascular diseases, coronary atherosclerosis diseases of heart and blood vessels, coronary artery disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all  of the following criteria: • Participant of a mass-participation exercise event with a: o Walking distance >=20 km o Cycling distance >=100 km o Running distance >=15 km • Age: >= 40 and <70 years old • Able to understand and perform study related procedures For Phase 2 of the study (i.e. assessment of (sub)clinical coronary artery  disease), the following additional criteria are present: • Free from (known) cardiovascular diseases

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in phase 2 of this study (CT scans): • Renal transplantation in the past • Contrast nephropathy in the past • eGFR

Design outcomes

Primary

Measure	Time frame
Baseline and post-exercise concentrations of high-sensitivity cTn I (hs-cTnI) and T (hs-cTnT) will be established for our primary aim.	—

Secondary

Measure	Time frame
Subsequently, the prevalence and magnitude of coronary artery calcification (i.e. Agatston score) and atherosclerotic plaque characteristics (density, phenotype (calcified/partially calcified/non-calcified), degree of stenosis, CT-derived fractional flow reserve), will be assessed in a subgroup of n=100 individuals with high versus n=50 with low post-exercise hs-cTnI concentrations. Finally, we will assess the incidence of major adverse cardiovascular events yearly and (cardiovascular and all-cause) mortality at 5-, 10-, 15-, and 20-years of follow-up.	—

Measure

Time frame

Subsequently, the prevalence and magnitude of coronary artery calcification (i.e. Agatston score) and atherosclerotic plaque characteristics (density, phenotype (calcified/partially calcified/non-calcified), degree of stenosis, CT-derived fractional flow reserve), will be assessed in a subgroup of n=100 individuals with high versus n=50 with low post-exercise hs-cTnI concentrations. Finally, we will assess the incidence of major adverse cardiovascular events yearly and (cardiovascular and all-cause) mortality at 5-, 10-, 15-, and 20-years of follow-up.

—

Countries

Netherlands

Contacts

Public ContactK.A.M. Nobelen

Radboud Universitair Medisch Centrum

treat.fysiol@radboudumc.nl024 3613416

Outcome results